Milos Aleksic
Overview
Explore the profile of Milos Aleksic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Wet B, Simmons R, Suckling R, Szoke-Kovacs R, Mansour S, Lepore M, et al.
Eur J Immunol
. 2024 Dec;
55(1):e202451230.
PMID: 39703131
The CD8 co-receptor exists as both an αα homodimer, expressed on subsets of specialized lymphoid cells, and as an αβ heterodimer, which is the canonical co-receptor on cytotoxic T-cells, tuning...
2.
Poole A, Karuppiah V, Hartt A, Haidar J, Moureau S, Dobrzycki T, et al.
Nat Commun
. 2022 Sep;
13(1):5333.
PMID: 36088370
Neoantigens derived from somatic mutations are specific to cancer cells and are ideal targets for cancer immunotherapy. KRAS is the most frequently mutated oncogene and drives the pathogenesis of several...
3.
Holland C, Crean R, Pentier J, de Wet B, Lloyd A, Srikannathasan V, et al.
J Clin Invest
. 2020 Apr;
130(5):2673-2688.
PMID: 32310221
Tumor-associated peptide-human leukocyte antigen complexes (pHLAs) represent the largest pool of cell surface-expressed cancer-specific epitopes, making them attractive targets for cancer therapies. Soluble bispecific molecules that incorporate an anti-CD3 effector...
4.
Coles C, Mulvaney R, Malla S, Walker A, Smith K, Lloyd A, et al.
J Immunol
. 2020 Feb;
204(7):1943-1953.
PMID: 32102902
The molecular rules driving TCR cross-reactivity are poorly understood and, consequently, it is unclear the extent to which TCRs targeting the same Ag recognize the same off-target peptides. We determined...
5.
Zhang H, Lim H, Knapp B, Deane C, Aleksic M, Dushek O, et al.
Sci Rep
. 2016 Oct;
6:35326.
PMID: 27734930
The interaction between the T cell antigen receptor (TCR) and antigenic peptide in complex with major histocompatibility complex (MHC) molecules is a crucial step in T cell activation. The relative...
6.
Yang H, Buisson S, Bossi G, Wallace Z, Hancock G, So C, et al.
Mol Ther
. 2016 Jul;
24(11):1913-1925.
PMID: 27401039
Persistence of human immunodeficiency virus (HIV) in a latent state in long-lived CD4+ T-cells is a major barrier to eradication. Latency-reversing agents that induce direct or immune-mediated cell death upon...
7.
McCormack E, Adams K, Hassan N, Kotian A, Lissin N, Sami M, et al.
Cancer Immunol Immunother
. 2012 Dec;
62(4):773-85.
PMID: 23263452
NY-ESO-1 and LAGE-1 are cancer testis antigens with an ideal profile for tumor immunotherapy, combining up-regulation in many cancer types with highly restricted expression in normal tissues and sharing a...
8.
Aleksic M, Liddy N, Molloy P, Pumphrey N, Vuidepot A, Chang K, et al.
Eur J Immunol
. 2012 Sep;
42(12):3174-9.
PMID: 22949370
T-cell destiny during thymic selection depends on the affinity of the TCR for autologous peptide ligands presented in the context of MHC molecules. This is a delicately balanced process; robust...
9.
Robert P, Aleksic M, Dushek O, Cerundolo V, Bongrand P, Anton van der Merwe P
Biophys J
. 2012 Feb;
102(2):248-57.
PMID: 22339861
Adaptive immune responses are driven by interactions between T cell antigen receptors (TCRs) and complexes of peptide antigens (p) bound to Major Histocompatibility Complex proteins (MHC) on the surface of...
10.
Dushek O, Aleksic M, Wheeler R, Zhang H, Cordoba S, Peng Y, et al.
Sci Signal
. 2011 Jun;
4(176):ra39.
PMID: 21653229
T cell activation, a critical event in adaptive immune responses, depends on productive interactions between T cell receptors (TCRs) and antigens presented as peptide-bound major histocompatibility complexes (pMHCs). Activated T...